Cardiac Biomarkers testing Market Outlook 2026 Opportunity and Growth Analysis with Top Key Vendors
According to a new report published by KD
Market Insights, titled, "Cardiac
Biomarkers Testing Market by
Type, Application, and Location of Testing: Global Opportunity Analysis and
Industry Forecast, 2019 - 2026," The global cardiac biomarkers testing
market size generated $7,638 million in 2018, and is projected to reach $18,232
million by 2026, growing at a CAGR of 11.4% from 2019 to 2026.
The cardiac troponins segment, both T and I, forefronts among all other cardiac
biomarker types, holding the largest share due to its strong performance, as
cardiac troponins are the most sensitive and specific biomarkers for subsequent
events of myocardium injury.
The global cardiac biomarkers testing market
has witnessed significant growth in the past few years and is anticipated to
continue to grow at a consistent pace, due to high prevalence of cardiac
diseases that widely remain undiagnosed. Large number of cardiac biomarkers in
pipeline, augmented patient awareness toward the importance of early detection
of cardiovascular diseases, and opportunities in untapped countries such as
India, China, and other Asia-Pacific countries are the key factors that
contribute toward the growth of the market.
In addition, introduction of novel cardiac
biomarkers for point of care (POC) testing and facilitating quick results for
chronic patients serve as opportunistic approaches to drive the market growth.
However, premium pricing of approved and novel single used cardiac biomarkers
and uncertain government regulation regarding the approval for biomarker tests
and assays are expected to hinder the market growth during the analysis period.
Presence of large undiagnosed patient
population, rise in incidence of cardiovascular diseases (CVDs), rapid
urbanization, increase in disposable income, improved government funding toward
healthcare, and surge in awareness about cardiac events, i.e., quick checkups
after the onset of chest pain are the prime reasons responsible for the market
growth in North America. Furthermore, the market growth is driven by novel
progress in the treatments with improved overall survival benefits using
multi-assay biomarkers. The survival benefit would be influential in governing
the peak sales and market penetration of novel approved cardiac biomarker-based
devices.
Based on cardiac biomarker type, the market is
segmented into creatine kinase (CK-MB), troponins T and I, myoglobin, BNPs,
IMA, and others. The IMA segment is expected to grow at high CAGR, as these
biomarkers improve the sensitivity and negative predictive value for the
diagnosis of myocardial ischemia when used in combination with standard cardiac
biomarkers.
The applications covered in the study include
myocardial infarction, congestive heart failure, acute coronary syndrome,
atherosclerosis, and others. The congestive heart failure segment is expected
to register the highest growth rate, owing to increased demand for biomarker
tests for early detection of heart failure.
North America led the global market in 2018,
due to high demand for cardiac testing, increase in prevalence rate of CVD, and
rise in awareness toward cardiac diagnostics solutions. Moreover, intensive
efforts taken by government and research institutes to deal with critical
cardiac diseases and increase in R&D activities related to cardiac
biomarkers are expected to boost the market growth in North America.
Browse Full Report & TOC: https://www.kdmarketinsights.com/product/cardiac-biomarkers-testing-market-amr
Key Findings of the Cardiac Biomarkers
Testing Market:
- By type, the troponin segment is projected
to dominate the market during the forecast period.
- The myocardial infarction segment is expected to grow more than twofold during the forecast period.
- Laboratory testing market is expected to garner XX of the overall market revenue by 2026.
- Based on location of testing segment, the point of care cardiac biomarker testing segment is projected to grow at a CAGR of XX% throughout the forecast period.
- Asia-Pacific region holds immense future market potential as there is a higher count of undiagnosed Cardiac patients diagnosed precisely
- The myocardial infarction segment is expected to grow more than twofold during the forecast period.
- Laboratory testing market is expected to garner XX of the overall market revenue by 2026.
- Based on location of testing segment, the point of care cardiac biomarker testing segment is projected to grow at a CAGR of XX% throughout the forecast period.
- Asia-Pacific region holds immense future market potential as there is a higher count of undiagnosed Cardiac patients diagnosed precisely
The report provides a comprehensive analysis
of the key players operating in the global cardiac biomarkers testing market ,
namely, Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton,
Dickinson and Company, Bio-Rad Laboratories, BioMerieux, PerkinElmer Inc., Tosoh
Corporation, Danaher Corporation, and Thermo Fisher Scientific.
About Us:
KD Market
Insights is one of the leading providers of market intelligence products
and services. We offer reports on over 10+ industries and update our collection
daily which helps our clients to access database of expert market insights on
global industries, companies, products, and trends.
Our
in-house research experts have a wealth of knowledge in their respective
domains. With KD Market Research, you always have the choice of getting
customized report free of cost (upto 10%). Our support team will help you
customize the report and scope as per your business needs. This ensures that
you are making the right purchase decision. Our clients list includes various
Fortune 500 companies and leading advisory firms.
Contact Us:
KD
Market Insights
90
State Street, Albany,
New
York, USA 12207
+1
(519) 300-1215
Comments
Post a Comment